OTCMKTS:XSNX NovAccess Global (XSNX) Stock Price, News & Analysis → The only accurate crypto trading system I know … (From Weiss Ratings) (Ad) Free XSNX Stock Alerts $0.0065 0.00 (0.00%) (As of 05/6/2024 ET) Add Compare Share Share Today's Range$0.0065▼$0.006550-Day Range$0.01▼$0.0352-Week Range$0.01▼$0.22Volume1 shsAverage Volume566,250 shsMarket Capitalization$250,185.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get NovAccess Global alerts: Email Address Ad Paradigm PressMy biggest AI fear (Do this before June 25th)These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.All the details are right here. About NovAccess Global Stock (OTCMKTS:XSNX)NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.Read More XSNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XSNX Stock News HeadlinesApril 30, 2024 | finance.yahoo.comNovAccess Global Announces New License to Advance its Immunotherapy PlatformApril 26, 2024 | americanbankingnews.comNovAccess Global Inc. (OTCMKTS:XSNX) Sees Large Decline in Short InterestMay 6, 2024 | The Oxford Club (Ad)Oil Surge Predicted... But Are You ReadyDo you own oil and gas stocks? Or are you thinking about buying some? If so, you need to see this.February 7, 2024 | msn.comNovAccess Global Faces Default and Uncertain Rescue DealJanuary 2, 2024 | msn.comNovAccess Global jumps on announcing $10.7 million financingJanuary 2, 2024 | finanznachrichten.deNovAccess Global Inc.: NovAccess Global Announces $10.7 Million FinancingJanuary 2, 2024 | finance.yahoo.comNovAccess Global Announces $10.7 Million FinancingDecember 1, 2023 | finance.yahoo.comNovAccess Global Inc. to Present at the December 7th Virtual Investor SummitMay 6, 2024 | The Oxford Club (Ad)Oil Surge Predicted... But Are You ReadyDo you own oil and gas stocks? Or are you thinking about buying some? If so, you need to see this.November 10, 2023 | finance.yahoo.comNovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory BoardNovember 2, 2023 | morningstar.comNovaccess Global Inc XSNXJuly 29, 2023 | finanznachrichten.deNovAccess Global Inc.: NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy PlatformJuly 27, 2023 | finance.yahoo.comNovAccess Global Partners with BCN Biosciences to Expand Immunotherapy PlatformJuly 13, 2023 | finance.yahoo.comNovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness DayJuly 6, 2023 | finance.yahoo.comXSNX - NovAccess Global Inc.June 16, 2023 | finanznachrichten.deNovAccess Global Inc.: NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine DivisionJune 16, 2023 | finance.yahoo.comNovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine DivisionJune 1, 2023 | finance.yahoo.comNovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare TherapiesMay 11, 2023 | finanznachrichten.deNovAccess Global Inc.: NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine AdvancementsMay 11, 2023 | finance.yahoo.comNovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine AdvancementsMarch 15, 2023 | finanznachrichten.deNovAccess Global Inc.: Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon AwardMarch 15, 2023 | finance.yahoo.comDr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon AwardFebruary 16, 2023 | finanznachrichten.deNovAccess Global Inc.: NovAccess Global to Present at World Orphan Drug CongressFebruary 16, 2023 | finance.yahoo.comNovAccess Global to Present at World Orphan Drug CongressFebruary 3, 2023 | finanznachrichten.deNovAccess Global Inc.: NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual CongressFebruary 3, 2023 | finance.yahoo.comNovAccess Global Leadership to Present at World Brain Mapping Foundation Annual CongressJanuary 5, 2023 | finance.yahoo.comNovAccess Global Announces Fireside Chat with Dr. Christopher Wheeler, the Company’s Lead Scientist and President of its StemVax Therapeutics DivisionSee More Headlines Receive XSNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovAccess Global and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/06/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:XSNX CUSIPN/A CIK1039466 Webwww.xsunx.com Phone(213) 642-9268Fax949-266-5823Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,720,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-877.60% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.58) per share Price / Book-0.01Miscellaneous Outstanding Shares38,490,000Free Float37,932,000Market Cap$250,185.00 OptionableNot Optionable Beta1.59 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Dwain K. Morris-Irvin M.P.H. (Age 56)MPH, Ph.D., CEO & Director Comp: $155.43kMr. Neil J. Laird (Age 71)Chief Financial Officer Dr. Christopher Wheeler Ph.D.President of Stemvax TherapeuticsKey CompetitorsGelStatOTCMKTS:GSACPredictive Technology GroupOTCMKTS:PREDSkinvisibleOTCMKTS:SKVIAmpio PharmaceuticalsNYSE:AMPETherapix BiosciencesOTCMKTS:TRPXDView All Competitors XSNX Stock Analysis - Frequently Asked Questions How have XSNX shares performed in 2024? NovAccess Global's stock was trading at $0.0201 at the start of the year. Since then, XSNX stock has decreased by 67.7% and is now trading at $0.0065. View the best growth stocks for 2024 here. Are investors shorting NovAccess Global? NovAccess Global saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 400 shares, a decrease of 99.4% from the March 31st total of 65,900 shares. Based on an average trading volume of 1,568,900 shares, the short-interest ratio is currently 0.0 days. View NovAccess Global's Short Interest. How were NovAccess Global's earnings last quarter? NovAccess Global Inc. (OTCMKTS:XSNX) released its earnings results on Tuesday, February, 27th. The company reported $0.01 EPS for the quarter. What other stocks do shareholders of NovAccess Global own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovAccess Global investors own include Co-Diagnostics (CODX), iBio (IBIO), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Kopin (KOPN), Ascent Solar Technologies (ASTI) and BioRestorative Therapies (BRTX). How do I buy shares of NovAccess Global? Shares of XSNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:XSNX) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersNo experience to confident trader, meet my student…Wealth Builders InstituteBiden’s $374B Giveaway Into This SectorDTIAI “wealth window” is closing June 25thParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingRevealed: The Unknown Biotech Powering AI in HealthcareBehind the MarketsThe only accurate crypto trading system I know …Weiss RatingsOil Surge Predicted... But Are You ReadyThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders Alliance Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovAccess Global Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.